Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067469 · ClinicalTrials.gov registry record · Phase 2
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
A Phase 2 study of Glioblastoma and Brain Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT01067469 is a Phase 2 study of Glioblastoma and Brain Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 83 participants, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01067469, a Phase 2 study of Glioblastoma and Brain Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if the combination of bevacizumab and lomustine can help to control glioblastoma. The safety of this combination will also be studied.
Conditions Studied
Interventions
- DRUG Lomustine
- DRUG Standard Dose Bevacizumab
- DRUG Low Dose Bevacizumab
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2010-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067469
The ClinicalTrials.gov registry entry for NCT01067469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (23% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Lomustine is the first listed.
NCT01067469 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01067469 about?
NCT01067469 is a clinical study titled "Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)". The goal of this clinical research study is to learn if the combination of bevacizumab and lomustine can help to control glioblastoma. The safety of this combination will also be studied.
What is the current status of trial NCT01067469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2010-01. Estimated completion is 2016-10.
What conditions does trial NCT01067469 study?
This clinical trial studies the following conditions: Glioblastoma, Brain Cancer.
What interventions are being tested in trial NCT01067469?
The interventions under investigation include: Lomustine (DRUG), Standard Dose Bevacizumab (DRUG), Low Dose Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01067469?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01067469 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.